PHAXIAM THERAPEUTICS S.A.

Highlights PHAXIAM Therapeutics S.A. Euronext Paris

Equities

PHXM

FR0011471135

Market Closed - Euronext Paris Other stock markets 09:05:27 07/05/2024 pm IST			5-day change	1st Jan Change
2.9 ^EUR	-0.85%		-1.86%	-36.96%

15/04	Phaxiam initiates trial in infective endocarditis	CF
15/04	PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Phaxiam initiates trial in infective endocarditis	15/04	CF
PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus	15/04	CI
PHAXIAM Therapeutics S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03	CI
PHAXIAM Therapeutics Completes Delisting of ADS From Nasdaq	11/03	MT
Global markets live: BAE Systems, HSBC, Nvidia, Tesla, Boeing...	21/02
Phaxiam to delist ADS from Nasdaq in March	21/02	CF

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW